YUTREPIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUTREPIA (YUTREPIA).
YUTREPIA (treprostinil) is a prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds and inhibits platelet aggregation. It binds to prostacyclin receptor (IP receptor), increasing cAMP in vascular smooth muscle cells, leading to vasodilation.
| Metabolism | Primarily hepatic metabolism via cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Treprostinil is extensively metabolized to inactive metabolites. |
| Excretion | Renal: 80% as unchanged drug; fecal: 15% as metabolites; biliary: <5%. |
| Half-life | Terminal elimination half-life: 12-15 hours (range 11-18 h) in adults; prolonged in renal impairment (CrCl <30 mL/min: up to 30 h). |
| Protein binding | 98% bound to albumin (primarily) and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2-1.5 L/kg (total body water). Indicates extensive tissue distribution. |
| Bioavailability | Oral: 70-80% (first-pass metabolism reduces from ~90% absorbed). |
| Onset of Action | Oral: 30-45 minutes; IV: 5-10 minutes. |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours. Clinical effects may persist longer due to active metabolite. |
0.6 mg/kg intravenously over 15 minutes every 3 weeks until disease progression or unacceptable toxicity.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, data not available; use with caution. |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate or severe hepatic impairment (Child-Pugh B or C), not studied; use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may have increased sensitivity. Monitor renal function and overall status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YUTREPIA (YUTREPIA).
| Breastfeeding | It is unknown whether treprostinil is excreted in human breast milk. No M/P ratio is available. Due to the potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends discontinuing breastfeeding or discontinuing the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | YUTREPIA (treprostinil) is a prostacyclin analog. Based on animal studies and limited human data, treprostinil is not expected to increase the risk of major birth defects. However, due to its vasodilatory effects, there is a potential for reduced uterine blood flow, which could theoretically affect fetal growth. No trimester-specific risks have been identified in humans; the drug should be used during pregnancy only if clearly needed. |
■ FDA Black Box Warning
YUTREPIA must be administered via continuous infusion (subcutaneous or intravenous) using an infusion pump. Abrupt withdrawal or sudden dose reduction may lead to worsening of pulmonary hypertension, which may be fatal. The infusion device must be carefully monitored to avoid delivery interruptions.
| Serious Effects |
Known hypersensitivity to treprostinil or any component of the formulation. Chronic use is contraindicated in patients with pulmonary veno-occlusive disease (PVOD) due to risk of pulmonary edema.
| Precautions | Risk of infection due to intravenous catheter use; chronic intravenous infusions may be associated with bloodstream infections and sepsis. Subcutaneous infusion site reactions (pain, erythema, induration) are common. Patients with hepatic impairment require dose adjustment. Patients with concurrent use of anticoagulants or antiplatelet agents may have increased bleeding risk. Monitor for signs of pulmonary edema if used in patients with pulmonary veno-occlusive disease. |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor blood pressure, heart rate, and signs of bleeding (treprostinil inhibits platelet aggregation). Fetal: Standard prenatal monitoring including ultrasound for fetal growth and amniotic fluid volume, as vasodilation may affect placental perfusion. Frequent fetal heart rate monitoring should be considered in pregnant women on treprostinil. |
| Fertility Effects | In animal studies, treprostinil did not impair fertility at doses up to 25 times the human exposure. No human data are available. There is no known effect on human fertility; however, underlying pulmonary arterial hypertension may itself impact fertility. |